Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
|Articles|September 16, 2015

RSV Vaccine Shows Promise in Preclinical Studies

Novovax’s investigational vaccine targeting respiratory syncytial virus (RSV) demonstrated clinical effectiveness in animal models.

Novovax announced on Sept. 15, 2015 that maternal immunization against respiratory syncytial virus (RSV) effectively demonstrated the transfer of placental anti-RSV antibodies to the pups of guinea pigs. The study findings were published in the peer-reviewed journal Vaccine.

RSV is the leading cause (of viral origin) of lower respiratory tract infections in infants worldwide, but direct immunization against RSV is typically not possible, as infant immune systems cannot handle such a vaccine. Thus, the study authors investigated the in-utero transfer of human serum immunoglobulin antibodies (IgG) against RSV from mother to child.

“The placental architecture in guinea pigs reflects the anatomy found in humans, making them an appropriate model to evaluate placental transfer of antibodies," commented Gregory M. Glenn, MD, senior vice-president of research and development at Novavax, in a press release. "These preclinical data further support our RSV F Vaccine maternal immunization program, and we look forward to announcing data from our Phase II clinical trial to protect infants via maternal immunization this quarter.”

Source: Novovax

 


Related to this article

The BioPharm Brief: A Matrix-Targeting ADC in Head and Neck Cancer, an RNAi Approval in Myasthenia Gravis, and AbbVie Bets on AND-Gated Bispecifics
Pyxis Oncology’s EDB+FN-targeting ADC micvotabart pelidotin shows a 39% confirmed response rate in previously treated head and neck cancer, FDA approves Regeneron and Alnylam’s cemdisiran (Livsayis) as the first RNAi therapy for generalized myasthenia gravis, and AbbVie partners with DISCO Pharmaceuticals on AND-gated bispecifics for solid tumors.